| domain | established finding | quantitative evidence | ontology suggestions | evidence scope/caveat |
|---|---|---|---|---|
| Disease definition | Autosomal dominant progressive external ophthalmoplegia (adPEO) is an adult-onset mitochondrial DNA maintenance disorder caused by heterozygous nuclear-gene defects, typically with secondary multiple mtDNA deletions in muscle and progressive ptosis/ophthalmoparesis (pqac-00000000, pqac-00000006) | Typical onset reported at 20–40 years in review literature; TWNK cohort mean onset 43 years, mean diagnosis 63 years (pqac-00000000, pqac-00000006) | HP:0000508 Ptosis; HP:0000602 Ophthalmoplegia; GO:0006260 DNA replication; GO:0005739 mitochondrion | Distinct from all-cause mitochondrial CPEO, which also includes mtDNA deletions/point mutations and recessive nuclear etiologies (pqac-00000002, pqac-00000003) |
| Core causal genes | Established adPEO genes include TWNK, POLG, POLG2, SLC25A4, DNA2, and RRM2B; OPA1 can produce a syndromic dominant phenotype with external ophthalmoplegia plus optic atrophy/deafness/ataxia and multiple mtDNA deletions (pqac-00000000, pqac-00000011) | No single gene frequency is established for all adPEO; in one TWNK-specific cohort, 25/25 had heterozygous TWNK variants (pqac-00000006, pqac-00000007) | HGNC gene symbols as listed; GO:0003678 DNA helicase activity (TWNK); GO:0003887 DNA-directed DNA polymerase activity (POLG); GO:0140355 ADP/ATP transmembrane transporter activity (SLC25A4) | Gene list is disease-level and heterogeneous; OPA1 should be annotated as syndromic/overlap rather than core isolated adPEO in all cases (pqac-00000000) |
| TWNK-specific variant data | TWNK-related adPEO is caused by heterozygous missense variants affecting mtDNA helicase function and replication (pqac-00000006) | 10 different TWNK mutations in 25 patients; most frequent c.1361T>G (p.Val454Gly) in 7 patients/6 families and c.1070G>C (p.Arg357Pro) in 7 patients/5 families; c.1121G>A (p.Arg374Gln) in 3 patients; c.1411T>G (p.Tyr471Asp) in 2 siblings (pqac-00000009) | Sequence Ontology: missense_variant; GO:0004386 helicase activity; GO:0006268 DNA unwinding involved in DNA replication | These frequencies apply to one Madrid laboratory cohort, not all adPEO populations (pqac-00000007, pqac-00000009) |
| Inheritance/family history | Inheritance is autosomal dominant with variable expressivity and adult presentation (pqac-00000000, pqac-00000011) | In TWNK cohort, 22/25 (88%) had first-degree relatives with ptosis and/or ophthalmoplegia; 64% female (16/25) (pqac-00000007) | HP:0000006 Autosomal dominant inheritance | Penetrance was not quantified in the retrieved evidence; sex distribution from one cohort should not be generalized (pqac-00000007) |
| Core phenotype | Hallmark phenotype is bilateral progressive ptosis with progressive external ophthalmoplegia; weakness and exercise intolerance are common extrasocular features (pqac-00000000, pqac-00000004, pqac-00000006) | TWNK cohort: ptosis 92%, PEO 80%, weakness 48%, exercise intolerance 28% (pqac-00000006) | HP:0000508 Ptosis; HP:0000602 Ophthalmoplegia; HP:0001324 Muscle weakness; HP:0003546 Exercise intolerance | Frequencies are strongest for TWNK-related adPEO; broader adPEO due to other genes may differ (pqac-00000000, pqac-00000006) |
| Additional/systemic phenotypes | adPEO may include bulbar dysfunction, hearing loss, ataxia, neuropathy, parkinsonism, cataracts, cardiac and respiratory involvement (pqac-00000000, pqac-00000004, pqac-00000005) | TWNK cohort: bulbar involvement 24%, cardiac 24%, respiratory 4%, neuropathy 8%, ataxia 4%, parkinsonism 4%; cataracts reported in 2 related patients (pqac-00000005, pqac-00000006) | HP:0002015 Dysphagia; HP:0000407 Sensorineural hearing impairment; HP:0001251 Ataxia; HP:0002355 Difficulty walking; HP:0000518 Cataract; HP:0011675 Arrhythmia/cardiac conduction abnormality | Systemic manifestations are variable and may be gene- and family-specific (pqac-00000000) |
| Pathology/biopsy | Skeletal muscle typically shows mitochondrial myopathy with ragged-red fibers, COX-negative fibers, and multiple mtDNA deletions (pqac-00000000, pqac-00000008, pqac-00000009) | In mitochondrial PEO series, biopsy showed mitochondrial changes in 95%; in TWNK cohort, all 19 available biopsies showed mitochondrial dysfunction and all 17 tested muscle samples had multiple mtDNA deletions (pqac-00000002, pqac-00000009) | HP:0003200 Ragged-red muscle fibers; HP:0003688 Abnormal muscle mitochondria; GO:0006119 oxidative phosphorylation | 95% biopsy yield was for mixed mitochondrial PEO, not adPEO alone; deletion testing is tissue-sensitive (pqac-00000002) |
| Mechanism/pathophysiology | Upstream defects fall into mtDNA replication/repair, nucleotide supply/balance, and mitochondrial dynamics/quality control; downstream consequence is multiple mtDNA deletions causing respiratory-chain deficiency and energy failure in high-demand muscle (pqac-00000000) | Respiratory complex activities can range from normal to ~50% of control means in affected muscle (pqac-00000000) | GO:0006260 DNA replication; GO:0007005 mitochondrion organization; GO:0006091 generation of precursor metabolites and energy; CL:0000187 skeletal muscle cell | Mechanistic framework is established for mtDNA-maintenance disorders broadly; adPEO-specific omics and cell-type-resolved datasets were not identified (pqac-00000000) |
| Electrophysiology/labs | EMG may show myopathic or mixed changes; CK and lactate can be normal or mildly elevated; GDF-15 may be elevated (pqac-00000000, pqac-00000005, pqac-00000008) | TWNK cohort: hyperCKemia 28%; mild hyperlactacidemia in 3/6 tested; GDF-15 elevated in 2/3 tested (1454–2727 pg/mL); EMG myopathic in 60%, neurogenic in 13%, normal in 27% of 15 tested (pqac-00000005, pqac-00000008) | LOINC/biomarkers: CK, lactate, GDF15; HP:0003236 Elevated serum creatine phosphokinase | Biomarker evidence is limited and from small tested subsets (pqac-00000008) |
| Diagnosis | Current understanding supports sequencing-based diagnosis, complemented by muscle biopsy and mtDNA rearrangement analysis when suspicion remains high; in one mitochondrial PEO algorithm, biopsy was proposed as first step because it enables mtDNA rearrangement studies (pqac-00000002, pqac-00000006) | Mixed mitochondrial PEO series achieved genetic diagnosis in 96%; biopsy informative in 95% (pqac-00000002) | NCIT: Genetic Testing; HP terms above; GO:0003723? not needed | These performance metrics are from all-cause mitochondrial PEO rather than strictly adPEO; practice has shifted toward broader NGS-first workflows in recent reviews (pqac-00000002, pqac-00000003) |
| Differential diagnosis | adPEO is commonly misdiagnosed as seronegative myasthenia gravis or oculopharyngeal muscular dystrophy (pqac-00000006) | In TWNK cohort, 56% were misdiagnosed before genetic confirmation: 36% myasthenia, 20% oculopharyngeal muscular dystrophy (pqac-00000006) | Differential ontology suggestions: HP:0000602 Ophthalmoplegia; disease comparators include myasthenia gravis and OPMD | Differential data derive from TWNK-related cases and specialist-center experience (pqac-00000006) |
| Management | No definitive disease-modifying therapy is established; management is supportive, includes lifestyle/risk modification, supplements used empirically in mitochondrial care, ptosis repair, and monitoring for multisystem complications (pqac-00000002, pqac-00000010) | No adPEO-specific response rates were identified in retrieved evidence (pqac-00000010) | NCIT: Supportive Care; NCIT: Blepharoplasty/Ptosis Repair; NCIT: Physical Therapy | Do not extrapolate LHON gene-therapy efficacy to adPEO; retrieved therapeutic advances largely concern other mitochondrial phenotypes (pqac-00000001, pqac-00000010) |
| Real-world implementation / trials | Real-world care currently relies on diagnostic genomics and symptom-directed interventions; relevant mitochondrial/PEO trials exist but are not adPEO genotype-specific efficacy trials (clinical-trial contexts summarized in prior retrieval) | Examples retrieved: NCT02161848 observational MRI study in CPEO, enrollment 133, completed; NCT04678115 severe blepharoptosis non-surgical treatment trial, enrollment 16, completed; NCT05162768 phase 3 elamipretide in primary mitochondrial disease from nuclear DNA mutations, enrollment 102, completed | NCIT: Magnetic Resonance Imaging; NCIT: Elamipretide; NCIT: Blepharoptosis intervention | Trial records were not specific to autosomal dominant PEO and do not establish standard-of-care efficacy for adPEO |
| Epidemiology | Robust adPEO-specific prevalence/incidence estimates were not identified in the retrieved evidence | Only broader CPEO estimates were found: incidence 1–2 per 100,000 and prevalence ~1 in 30,000 or 3.4 per 100,000 in review sources (pqac-00000002, pqac-00000003) | MONDO/Orphanet term suggestion should await authoritative identifier confirmation | These figures apply to mitochondrial CPEO broadly, not specifically to autosomal dominant PEO; epidemiology remains a knowledge gap for the AD subtype (pqac-00000002, pqac-00000003) |


*Table: This table summarizes established, citable knowledge for autosomal dominant progressive external ophthalmoplegia, emphasizing what is supported directly for the AD subtype versus broader mitochondrial CPEO. It is useful for populating structured disease fields while preserving important scope caveats and evidence gaps.*